AstraZeneca
AstraZeneca Inks $1.35B Deal with Alteogen for Subcutaneous Cancer Drugs Amid Industry Patent Disputes
AstraZeneca, Alteogen, subcutaneous cancer drugs, licensing agreement, patent dispute, Merck, Halozyme, hyaluronidase enzyme
AstraZeneca to acquire FibroGen’s China unit for $160M
China, AstraZeneca, FibroGen, FibroGen ‘s, roxadustat
AstraZeneca Acquires FibroGen’s China Unit for $160 Million, Gaining Full Control of Anemia Drug Roxadustat
AstraZeneca, FibroGen, China, acquisition, roxadustat, anemia, chronic kidney disease, pharmaceutical industry
AstraZeneca Shares Rise as China Investigation Impact Appears Limited
AstraZeneca, China investigation, share price, financial performance, import taxes, investor confidence
AstraZeneca Discontinues Vemircopan, Takes $753M Charge on Former Alexion Asset
AstraZeneca, Alexion, vemircopan, complement inhibitor, drug discontinuation, impairment charge, rare diseases, pharmaceutical industry
AstraZeneca Cancels £450 Million UK Vaccine Plant Expansion Amid Government Funding Reduction
AstraZeneca, vaccine manufacturing, UK investment, government funding, Labour administration, economic growth, pharmaceutical industry
Enhertu Secures 7th FDA Approval for Expanded Use in HER2-Low and HER2-Ultralow Breast Cancer
Enhertu, FDA Approval, HER2-Low, HER2-Ultralow, Breast Cancer, AstraZeneca, Daiichi Sankyo
AstraZeneca Invests $570M in Canadian Expansion, Creating 700 New Jobs
AstraZeneca, Canadian expansion, $570M investment, 700 new jobs, life sciences, R&D, clinical trials, pharmaceutical industry
AstraZeneca Secures Full FDA Approval for Lymphoma Treatment Selected by CMS
AstraZeneca, FDA Approval, Lymphoma Treatment, CMS-Selected
AstraZeneca’s Calquence Gains FDA Approval as First-Line Treatment for Mantle Cell Lymphoma
AstraZeneca, Calquence, acalabrutinib, BTK inhibitor, mantle cell lymphoma, first-line treatment, FDA approval